DERM
Journey Medical Corporation7.88
+0.18+2.34%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
213.83MP/E (TTM)
-Basic EPS (TTM)
-0.35Dividend Yield
0%Recent Filings
8-K
10-Q
8-K
New ATM sales agreement signed
Journey Medical Corporation entered a new At Market Issuance Sales Agreement on August 28, 2025, with B. Riley Securities and Lake Street Capital Markets, allowing sales of up to 3,750,000 common shares at market prices for flexible capital raising. The prior agreement with B. Riley, under which 4,121,318 shares were sold since December 2022, was terminated that day. This setup bolsters liquidity yet risks diluting shareholders.
8-K
Q2 revenues hit $15M
Journey Medical reported Q2 2025 net product revenues of $15.0 million, edging up from $14.9 million a year ago, fueled by $2.8 million from Emrosi's first full quarter post its April 7 launch. Gross margin climbed to 67% on better product mix, yet SG&A rose $1.6 million to $11.9 million amid commercialization costs, yielding a $3.8 million net loss. Emrosi snagged over 100 million covered lives by July. Russell Index inclusion boosts visibility. Payer adoption accelerates growth.
10-Q
Q2 FY2025 results
Journey Medical's Q2 revenue edged up 1% year-over-year to $15.0M, fueled by $2.8M from the new Emrosi launch, though Accutane sales dropped 41% amid competition; gross margin improved as costs fell 14% to $4.9M. Operating loss narrowed slightly to $2.9M from $2.9M, while YTD figures show sharper progress with revenue at $28.1M (up 1%) and operating loss halved to $6.2M versus $13.0M, thanks to slashed R&D spend. Diluted EPS held at -$0.16 on 23.3M shares, matching YTD trends without dilution quirks. Cash stayed flat at $20.3M, with $3.8M operating outflow offset by $4.0M ATM equity raises; $25.0M SWK term loan (due 2027, SOFR+7.75%) carries $21.4M long-term net, and covenants hold firm. Emrosi hit FDA approval November 2024, triggering $15.0M milestone to Dr. Reddy's and recognizing intangibles amortized over 3-15 years. Yet generic rivals keep pressuring legacy lines.
IPO
Employees
Sector
Industry
AMRX
Amneal Pharmaceuticals, Inc.
12.17-0.29
BGM
BGM Group Ltd.
5.01-0.16
DRMA
Dermata Therapeutics, Inc.
2.32-0.16
FBIO
Fortress Biotech, Inc.
3.51+0.19
GALDY
GALDERMA GROUP AG
40.96-1.03
JNJ
Johnson & Johnson
209.30-4.87
ORGO
Organogenesis Holdings Inc.
5.17+0.34
RMTI
Rockwell Medical, Inc.
0.83-0.03
SNOA
Sonoma Pharmaceuticals, Inc.
3.38-0.03
SSKN
Strata Skin Sciences, Inc.
1.33-0.03